| Original language | English |
|---|---|
| Pages (from-to) | 1119-1134 |
| Number of pages | 16 |
| Journal | Annals of Oncology |
| Volume | 31 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - 1 Sept 2020 |
Keywords
- chemotherapy
- hormone therapy
- prostate cancer
- radiotherapy
- surgery
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Annals of Oncology, Vol. 31, No. 9, 01.09.2020, p. 1119-1134.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Prostate cancer
T2 - ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
AU - ESMO Guidelines Committee
AU - Parker, C.
AU - Castro, E.
AU - Fizazi, K.
AU - Heidenreich, A.
AU - Ost, P.
AU - Procopio, G.
AU - Tombal, B.
AU - Gillessen, S.
N1 - Funding Information: The ESMO Guidelines Committee would like to thank the ESMO Faculty and other experts who provided critical reviews of these ESMO Clinical Practice Guidelines. No external funding has been received for the preparation of these guidelines. Production costs have been covered by ESMO from central funds. CP has reported honoraria from Bayer, Janssen and Advanced Accelerator Applications (AAA) and research grants from Bayer; EC has reported honoraria from Astellas, AstraZeneca, Bayer, Janssen and Pfizer and research grants from AstraZeneca, Bayer and Janssen; KF has reported participation to advisory boards/honoraria for Astellas, AAA, Bayer, Clovis, Curevac, Incyte, Janssen, Merck Sharp & Dohme, Orion, Sanofi; AH has reported paid consultancy for Amgen, Astellas, Ferring, Ipsen, Jansen, Pfizer, Sanofi, Takeda and has received research grants from Astellas and Sanofi; PO has reported institutional honoraria from Janssen, Bayer, Ferring Pharmaceuticals for consultancy and research grants from Merck and Varian; GP has reported advisory boards/honoraria from AstraZeneca, Bayer, Bristol-Myers Squibb, Ipsen, Janssen, Merck Sharp & Dohme, Novartis and Pfizer; BT has reported paid consultancy for Amgen, Bayer, Astellas, Ferring Pharmaceuticals, Janssen, Sanofi-Genzyme, Steba and that he is an investigator for Bayer, Astellas, Ferring Pharmaceuticals, Myovant Sciences, Janssen, Sanofi-Genzyme and Steba; SG has reported advisory role (including independent data monitoring committees) and speakers bureau for AAA International, Active Biotech AB, Amgen, Astellas Pharma, Bayer, Bristol-Myers Squibb, CellSearch, Clovis, CureVac, Dendreon, ESSA Pharma, Ferring, Innocrin Pharmaceuticals, Janssen Cilag, MaxiVAX, Millenium, Nectar, Novartis, Orion, Pfizer, ProteoMediX, Roche, Sanofi, and has reported being the co-inventor for a method for biomarker discovery (on patent application WO 2009138392 A1, granted in China, Europe, Japan and the USA).
PY - 2020/9/1
Y1 - 2020/9/1
KW - chemotherapy
KW - hormone therapy
KW - prostate cancer
KW - radiotherapy
KW - surgery
UR - http://www.scopus.com/inward/record.url?scp=85089363610&partnerID=8YFLogxK
U2 - 10.1016/j.annonc.2020.06.011
DO - 10.1016/j.annonc.2020.06.011
M3 - Article
C2 - 32593798
AN - SCOPUS:85089363610
SN - 0923-7534
VL - 31
SP - 1119
EP - 1134
JO - Annals of Oncology
JF - Annals of Oncology
IS - 9
ER -